Williams KM - Search Results

1

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith MW, Wang N, Roberts DM, Graham GG, Williams KM, Day RO. Ramasamy SN, et al. Among authors: williams km. Drug Saf. 2013 Oct;36(10):953-80. doi: 10.1007/s40264-013-0084-0. Drug Saf. 2013. PMID: 23873481 Review.

2

Open-label extension studies: do they provide meaningful information on the safety of new drugs?

Day RO, Williams KM. Day RO, et al. Among authors: williams km. Drug Saf. 2007;30(2):93-105. doi: 10.2165/00002018-200730020-00001. Drug Saf. 2007. PMID: 17253876 Review.

3

A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Lee MH, Graham GG, Williams KM, Day RO. Lee MH, et al. Among authors: williams km. Drug Saf. 2008;31(8):643-65. doi: 10.2165/00002018-200831080-00002. Drug Saf. 2008. PMID: 18636784 Review.

4

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.

Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Stocker SL, et al. Among authors: williams km. J Rheumatol. 2011 May;38(5):904-10. doi: 10.3899/jrheum.101160. Epub 2011 Feb 1. J Rheumatol. 2011. PMID: 21285173 Clinical Trial.

5

The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis.

Duong JK, Furlong TJ, Roberts DM, Graham GG, Greenfield JR, Williams KM, Day RO. Duong JK, et al. Among authors: williams km. Drug Saf. 2013 Sep;36(9):733-46. doi: 10.1007/s40264-013-0038-6. Drug Saf. 2013. PMID: 23549904

6

Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

Graham GG, Kannangara DR, Stocker SL, Portek I, Pile KD, Indraratna PL, Datta I, Williams KM, Day RO. Graham GG, et al. Among authors: williams km. Br J Clin Pharmacol. 2013 Dec;76(6):932-8. doi: 10.1111/bcp.12126. Br J Clin Pharmacol. 2013. PMID: 23590252 Free PMC article. Clinical Trial.

7

An audit of a therapeutic drug monitoring service for allopurinol therapy.

Kannangara DR, Ramasamy SN, Ray JE, Jones G, Graham GG, Williams KM, Day RO. Kannangara DR, et al. Among authors: williams km. Ther Drug Monit. 2013 Dec;35(6):863-6. doi: 10.1097/FTD.0b013e318299920a. Ther Drug Monit. 2013. PMID: 24263644

8

Xanthine oxidoreductase and its inhibitors: relevance for gout.

Day RO, Kamel B, Kannangara DR, Williams KM, Graham GG. Day RO, et al. Among authors: williams km. Clin Sci (Lond). 2016 Dec 1;130(23):2167-2180. doi: 10.1042/CS20160010. Clin Sci (Lond). 2016. PMID: 27798228 Review.

9

Allopurinol: insights from studies of dose-response relationships.

Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG. Day RO, et al. Among authors: williams km. Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):449-462. doi: 10.1080/17425255.2017.1269745. Epub 2016 Dec 20. Expert Opin Drug Metab Toxicol. 2017. PMID: 27927043 Review.

10

Individualising the dose of allopurinol in patients with gout.

Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, Barclay ML, Williams KM, Stamp LK, Day RO. Kannangara DRW, et al. Among authors: williams km. Br J Clin Pharmacol. 2017 Sep;83(9):2015-2026. doi: 10.1111/bcp.13307. Epub 2017 May 28. Br J Clin Pharmacol. 2017. PMID: 28417592 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

591 results

Search Page